TY - JOUR
T1 - Changes in human immunodeficiency virus type 1 virus lead during mobilization and harvesting of hemopoietic progenitor cells
AU - Campbell, Thomas B.
AU - Sevin, Anne
AU - Coombs, Robert W.
AU - Peterson, Gregory C.
AU - Rosandich, Mary
AU - Kuritzkes, Daniel R.
AU - Mladenovic, Jeannette
AU - Landay, Alan
AU - Wong, Roberta
AU - Ambruso, Daniel
AU - Miles, Steve
AU - Pomerantz, Roger J.
AU - Schooley, Robert T.
PY - 2000/1/1
Y1 - 2000/1/1
N2 - Genetic modification of hemopoietic progenitor cells ex vivo, followed by the infusion of the genetically modified cells into the human immunodeficiency virus-1 (HIV-1) infected donor, has been proposed as a treatment for HIV-1 infection. The current study was undertaken to evaluate the effect of hemopoietic stem cell mobilization and harvesting on HIV-1 replication in persons with HIV-1 infection. Eighteen HIV-1-infected persons received recombinant granulocyte colony-stimulating factor (G-CSF; Filgrastim) 10 μg/kg per day, for 7 days. On days 4 and 5, peripheral blood mononuclear cells were harvested by leukapheresis. The CD4+ lymphocyte count at entry was >500/μL for 6 subjects, 200 to 500/μL for 6 subjects, and <200/μL for 6 subjects. For 9 of 18 subjects, plasma HIV-1 RNA levels increased 4- to 100-fold (>0.6 log10) above baseline between days 4 and 7 and returned to baseline by day 27. Significant increases of plasma HIV-1 RNA levels occurred in 5 subjects despite 3-drug antiretroviral therapy. Changes in CD4+ and CD34+ cells during mobilization and harvesting were similar in all subjects whether they had or did not have increased plasma HIV-1 RNA levels. Thus, mobilization and harvesting of bone marrow progenitor cells from persons infected with HIV-1 induced a transient increase in viral replication in some patients but was not associated with adverse effects.
AB - Genetic modification of hemopoietic progenitor cells ex vivo, followed by the infusion of the genetically modified cells into the human immunodeficiency virus-1 (HIV-1) infected donor, has been proposed as a treatment for HIV-1 infection. The current study was undertaken to evaluate the effect of hemopoietic stem cell mobilization and harvesting on HIV-1 replication in persons with HIV-1 infection. Eighteen HIV-1-infected persons received recombinant granulocyte colony-stimulating factor (G-CSF; Filgrastim) 10 μg/kg per day, for 7 days. On days 4 and 5, peripheral blood mononuclear cells were harvested by leukapheresis. The CD4+ lymphocyte count at entry was >500/μL for 6 subjects, 200 to 500/μL for 6 subjects, and <200/μL for 6 subjects. For 9 of 18 subjects, plasma HIV-1 RNA levels increased 4- to 100-fold (>0.6 log10) above baseline between days 4 and 7 and returned to baseline by day 27. Significant increases of plasma HIV-1 RNA levels occurred in 5 subjects despite 3-drug antiretroviral therapy. Changes in CD4+ and CD34+ cells during mobilization and harvesting were similar in all subjects whether they had or did not have increased plasma HIV-1 RNA levels. Thus, mobilization and harvesting of bone marrow progenitor cells from persons infected with HIV-1 induced a transient increase in viral replication in some patients but was not associated with adverse effects.
UR - http://www.scopus.com/inward/record.url?scp=0033985449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033985449&partnerID=8YFLogxK
U2 - 10.1182/blood.v95.1.48
DO - 10.1182/blood.v95.1.48
M3 - Article
C2 - 10607683
AN - SCOPUS:0033985449
SN - 0006-4971
VL - 95
SP - 48
EP - 55
JO - Blood
JF - Blood
IS - 1
ER -